ArticleFrontiers in oncology2025
Liposomal irinotecan with fluorouracil and leucovorin as salvage treatment for advanced biliary tract cancer refractory to gemcitabine and cisplatin.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The combination of liposomal irinotecan with fluorouracil and leucovorin (Nal-IRI/FL) has shown efficacy in phase II trials for advanced biliary tract cancer (BTC) following gemcitabine-cisplatin (GP) therapy. However, its effectiveness and safety in real-world clinical settings have not been well established. This study aimed to assess the real-world outcomes of Nal-IRI/FL in BTC patients who experienced disease progression after gemcitabine-based treatment. Materials and methods: This retrospective, multicenter study evaluated patients with advanced BTC who received Nal-IRI/FL following progression on GP-based therapy between January 2022 and December 2024. Survival outcomes, radiologic responses, toxicities, and molecular alterations were evaluated, with key findings compared against those reported in prior clinical trials. Results: A total of 93 patients were included. The median progression-free survival (PFS) and overall survival (OS) were 2.1 and 4.2 months, respectively. Among 76 radiologic response evaluable patients, median PFS and OS were 2.5 and 5.0 months. The disease control rate was 40.8%, and objective response rate was 7.5%. Higher disease burden and poor performance status were associated with inferior outcomes. Efficacy did not significantly differ between second- and third-line settings or based on Conclusions: Nal-IRI/FL showed modest effectiveness in real-world settings, with outcomes generally less favorable than clinical trials, potentially reflecting patient characteristics. Its efficacy was consistent across treatment lines and mutation subgroups, including patients with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.